|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:ATCCode
|
N05CH02
|
|
gptkbp:bioavailability
|
1.8%
|
|
gptkbp:brand
|
gptkb:Rozerem
|
|
gptkbp:CASNumber
|
196597-26-9
|
|
gptkbp:chemicalFormula
|
indane derivative
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:drugClass
|
melatonin receptor agonist
|
|
gptkbp:eliminationHalfLife
|
1-2.6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C16H21NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ramelteon
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:meltingPoint
|
180-181°C
|
|
gptkbp:metabolism
|
gptkb:CYP1A2
gptkb:CYP2C9
gptkb:CYP3A4
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
82%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
6918293
5293736
DB00966
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
somnolence
|
|
gptkbp:synonym
|
TAK-375
|
|
gptkbp:target
|
gptkb:MT1_receptor
gptkb:MT2_receptor
|
|
gptkbp:UNII
|
2ZZ366QI8W
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:MT1_receptor
|
|
gptkbp:bfsLayer
|
7
|